Remove aelis-farma-announces-positive-results-of-non-clinical-studies-required-by-regulatory-agencies-to-enter-its-first-cb1-ssi-aef0117-in-phase-3-clinical-trial-for-the-treatment-of-cannabis-use-disorder
article thumbnail

Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder

Medical Marijuana Program Connection

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today. Read More